Apyx Medical CORP 8-K filings

Apyx Medical Corporation's 2026 Annual Meeting saw strong shareholder approval for director elections, auditor ratification, executive compensation, and the 2026 Share Incentive Plan.

Apyx Medical Corporation announced on July 24, 2026, the reconstitution of its Board of Directors' standing committees, including the Audit, Governance, Regulatory Compliance, and Compensation Committees.

Apyx Medical Corporation announced new clinical data published in Aesthetic Surgery Journal Open Forum demonstrating significant improvements in cellulite and skin laxity using a combination treatment approach.

Apyx Medical Corporation announced the publication of a study in Plastic and Reconstructive Surgery - Global Open, indicating Renuvion combined with liposuction leads to higher patient satisfaction and fewer revisions.

Apyx Medical Corporation announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, a move expected to enhance market demand and streamline surgical procedures.

Apyx Medical Corporation announced first quarter 2026 financial results, reporting $12.5 million in total revenue, a 32.4% increase year-over-year, and raised its full-year revenue guidance.

Apyx Medical Corporation announced preliminary, unaudited revenue results for Q4 and full year 2025, showing significant growth in Surgical Aesthetics driven by the AYON launch.

Apyx Medical Corporation filed an amendment to its Certificate of Incorporation, removing Article EIGHTH.

Apyx Medical Corporation announced the pricing and closing of an underwritten public offering of 2.76 million common shares, raising approximately $9.4 million in net proceeds for working capital and general corporate purposes.

Apyx Medical Corporation announced robust third-quarter 2025 financial results, driven by the successful U.S. launch of its AYON Body Contouring System and an upward revision of its full-year revenue guidance.

Apyx Medical Corporation's stockholders approved the election of five directors, ratified RSM US LLP as auditor, and endorsed executive compensation and a charter amendment at their annual meeting.

Apyx Medical Corporation reported Q2 2025 financial results, including a reduced net loss and increased full-year revenue guidance driven by strong initial demand for its new AYON Body Contouring System.

Apyx Medical Corporation announces FDA clearance for its AYON Body Contouring System, an all-in-one platform for aesthetic surgical procedures.

Apyx Medical Corporation announced its first quarter 2025 financial results, highlighting growth in the Advanced Energy segment and a significant reduction in net loss.

Apyx Medical reports favorable clinical outcomes and safety data from two peer-reviewed studies evaluating Renuvion's use in abdominal body contouring procedures, including lipoabdominoplasty.

Apyx Medical Corporation announced its Q4 and full year 2024 financial results, highlighting increased single-use handpiece shipments and the submission of a 510(k) premarket notification to the FDA for the AYON Body Contouring System.

Apyx Medical Corporation has appointed Shawn Roman as Chief Operating Officer, effective January 28, 2025, and entered into an employment agreement outlining his compensation, benefits, and terms of employment.

Apyx Medical announced preliminary revenue results for Q4 and full year 2024, showing a decrease in total revenue year-over-year despite growth in the Advanced Energy segment quarter-over-quarter.

Apyx Medical has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, an all-in-one platform for surgical body contouring.

Apyx Medical announced a $7 million registered direct offering, a cost-saving restructuring program, and updated financial guidance for 2024 and 2025.

Apyx Medical Corporation held its annual meeting on August 8, 2024, where stockholders elected eight directors and ratified the appointment of RSM US LLP as the company's independent auditor.

Apyx Medical reported a 10% year-over-year decrease in total revenue for the second quarter of 2024, alongside an updated full-year financial outlook.

Apyx Medical reported a 16% year-over-year decrease in total revenue for the first quarter of 2024, while reaffirming its full-year financial guidance.

Apyx Medical Corporation announced the retirement of its Chairman, Andrew Makrides, and the appointment of Stavros Vizirgianakis as his successor, effective May 7, 2024.

Apyx Medical reported a 16% increase in fourth-quarter revenue but a widening net loss, and provided a 2024 revenue outlook that suggests a potential decrease.

Apyx Medical's Renuvion technology will be featured in three educational sessions at the American Academy of Cosmetic Surgery's annual meeting, highlighting a study showing fewer adverse events compared to a competing technology.

Apyx Medical's Renuvion technology shows no increased risk when used for soft tissue contraction after liposuction, according to a peer-reviewed study.